CVS Health Corp

CVS Health’s diversified PBM, clinic expansion and recent analyst target‑price cut: how retail security, regulatory risk and inflation shape its future growth.

CVS Health faces a safety crisis after a clerk’s death in a Lindenhurst pharmacy. This article analyzes regulatory, PR, and economic impacts, and offers concrete steps to boost night‑shift safety, employee support, and stakeholder engagement to prot…

CVS Health faces scrutiny after a fatal store stabbing, revealing gaps in safety protocols and transparency that threaten reputation, regulatory compliance, and long‑term profits.

Louisiana’s CVS Health settlement eases PBM scrutiny while analysts raise target prices amid strong margins, expanded MMR services and tech‑driven care coordination.

CVS Health Corp. has announced a strategic contraction of its Medicare Advantage operations, reducing coverage to 43 states and 2,159 counties in 2026, in response to tightened federal reimbursement rates and a shift towards cost efficiency.

CVS Health is scaling back its Medicare Advantage operations, reducing the number of counties it serves and limiting prescription drug plans to 43 states, as the company and its competitors adapt to declining federal reimbursement rates and shifting…

CVS Health Corp has reached a 52-week high, with analysts remaining bullish on the company’s future despite controversy over its decision to limit access to the updated Covid vaccine.

CVS Health’s stock price has surged to a new buy point, but a controversial decision to exclude coverage for a new HIV drug due to its high price has raised concerns about the company’s overall performance.

CVS Health Corp has received a stock rating upgrade to Outperform from Baird, driven by its growth potential in the Medicare Advantage market and strategic expansion plans.

CVS Health Corp’s stock is poised for growth, driven by its focus on telehealth and telemedicine, with analysts predicting a bright future for the company.